Over the past few months we have heard quite a bit about AI agents and agentic development ... will these common paths be easier to manage and scale, but they should also be easier to diagnose ...

This article explores how digital maturity in process design and parameter management can drive significant time and cost ...

When Genentech licensed experimental drug ... large-scale experiments and we use these experiments in order to understand the biology.'" Executives and industry experts caution that AI adoption ...

Vijay Pande, PhD, founding investor of Andreessen Horowitz's Bio + Health fund and a general partner with the tech venture ...

This is particularly promising for 49% of surveyed organizations that scored in the mid-range or “emerging” maturity category having succeeded in digital transformations yet still struggle to scale ..

Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...

From streamlining clinical trials to evaluating drug repurposing ... to ever lead flagship AI programs. Recognising larger scale inefficiencies in the field of drug development, Latshaw pursued ...

drug discovery, development, manufacturing, and quality control. This collaboration combines the power of Microsoft’s secure Azure platform with the Tetra Scientific Data and AI Cloud ™ to ...

Additionally, the modified Rankin Scale ... wave of AI-driven drug candidates has fueled both optimism and skepticism, given past “breakthroughs” that failed to solve drug development ...

Article on tech giants' FY25 capex projections and AI data center advances. Nvidia Corporation stock analysis included. Click ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger ...